{"issuance_frequency":"","notes_translated":{"fr":"Fournir des directives aux promoteurs qui présentent des demandes d'essais cliniques (DEC) à Santé Canada en décrivant les exigences techniques relatives à la qualité (chimie et fabrication) conformément aux dispositions du titre C.05 du Règlement sur les aliments et drogues.","en":"To assist submission sponsors in preparing Clinical Trial Applications (CTAs) filed with Health Canada by outlining the Quality (chemistry and manufacturing) technical requirements for CTAs pursuant to Division C.05 of the Food and Drug Regulations."},"issn":"","imso_approval":"true","isbn":"","creator":"","org_section":{"fr":"","en":""},"jurisdiction":"federal","private":false,"maintainer_email":"open-ouvert@tbs-sct.gc.ca","num_tags":0,"edition":"","frequency":"as_needed","data_series_issue_identification":{"fr":"","en":""},"contributor":{"fr":"","en":""},"maintainer":null,"ready_to_publish":"true","id":"ea7ff183-a4a0-4961-b283-a382559a00aa","metadata_created":"2021-06-02T15:12:00.318292","subject":["health_and_safety"],"pspc_identification_number":"","metadata_modified":"2021-06-02T15:12:00.318299","author":null,"author_email":null,"geographic_region":[],"portal_release_date":"2021-06-02","digital_object_identifier":"","state":"active","version":null,"keywords":{"fr":["document d'orientation","exigences techniques de qualité","chimie et fabrication","applications d'essais cliniques","CTA","produits pharmaceutiques"],"en":["guidance document","quality technical requirements","chemistry and manufacturing","clinical trial applications","CTAs","Pharmaceuticals"]},"relationships_as_object":[],"creator_user_id":"2dc5a12f-2a6f-4822-8514-165ea6bb05d9","title_translated":{"fr":"Ligne directrice en matière de qualité (chimie et fabrication) : demandes d'essais cliniques (DEC) pour les produits pharmaceutiques","en":"Guidance Document - Quality (Chemistry and Manufacturing) Guidance: Clinical Trial Applications (CTAs) for Pharmaceuticals"},"type":"info","resources":[{"cache_last_updated":null,"unique_identifier":"","package_id":"ea7ff183-a4a0-4961-b283-a382559a00aa","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"ec6c697c-6818-4ab4-a8ed-e5f899a50f6b","related_relationship":"","name_translated":{"fr":"Ligne directrice en matière de qualité (chimie et fabrication) : demandes d'essais cliniques (DEC) pour les produits pharmaceutiques","en":"Guidance Document - Quality (Chemistry and Manufacturing) Guidance: Clinical Trial Applications (CTAs) for Pharmaceuticals"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance Document - Quality (Chemistry and Manufacturing) Guidance: Clinical Trial Applications (CTAs) for Pharmaceuticals","language":["en"],"created":"2021-06-02T15:12:00.425052","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/clinical-trials/quality-chemistry-manufacturing-guidance-clinical-trial-applications-pharmaceuticals.html#a11","last_modified":null,"position":0,"revision_id":"563cbbbe-124f-44f6-9c1d-6182cd3807ad","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"ea7ff183-a4a0-4961-b283-a382559a00aa","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"313a5f4c-37c8-4c70-af82-9dee1407989d","related_relationship":"","name_translated":{"fr":"Ligne directrice en matière de qualité (chimie et fabrication) : demandes d'essais cliniques (DEC) pour les produits pharmaceutiques","en":"Guidance Document - Quality (Chemistry and Manufacturing) Guidance: Clinical Trial Applications (CTAs) for Pharmaceuticals"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance Document - Quality (Chemistry and Manufacturing) Guidance: Clinical Trial Applications (CTAs) for Pharmaceuticals","language":["fr"],"created":"2021-06-02T15:12:00.425057","url":"https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/demandes-presentations/lignes-directrices/essais-cliniques/revisee-ligne-directrice-matiere-qualite-chimie-fabrication-demandes-essais-cliniques-produits-pharmaceutiques.html#a11","last_modified":null,"position":1,"revision_id":"563cbbbe-124f-44f6-9c1d-6182cd3807ad","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"ea7ff183-a4a0-4961-b283-a382559a00aa","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"f13e7137-da36-473e-bbc1-5e84fde65ef3","related_relationship":"","name_translated":{"fr":"Sommaire global de la qualité - Entités chimiques Demande d'essai clinique - Phase I","en":"Quality Overall Summary - Chemical Entities Clinical Trial Application - Phase I (QOS-CE (CTA - Phase I)"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Quality Overall Summary - Chemical Entities Clinical Trial Application - Phase I (QOS-CE (CTA - Phase I)","language":["en"],"created":"2021-06-02T15:12:00.425060","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/templates/quality-overall-summary-chemical-entities-clinical-trial-application-phase-1.html","last_modified":null,"position":2,"revision_id":"563cbbbe-124f-44f6-9c1d-6182cd3807ad","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"ea7ff183-a4a0-4961-b283-a382559a00aa","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"427de06e-e218-41a6-8000-c0181109f55f","related_relationship":"","name_translated":{"fr":"Sommaire global de la qualité - Entités chimiques Demande d'essai clinique - Phase I","en":"Quality Overall Summary - Chemical Entities Clinical Trial Application - Phase I (QOS-CE (CTA - Phase I)"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Quality Overall Summary - Chemical Entities Clinical Trial Application - Phase I (QOS-CE (CTA - Phase I)","language":["fr"],"created":"2021-06-02T15:12:00.425062","url":"https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/demandes-presentations/modeles/sommaire-global-qualite-entites-chimiques-demande-essai-clinique-phase-1.html","last_modified":null,"position":3,"revision_id":"563cbbbe-124f-44f6-9c1d-6182cd3807ad","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"ea7ff183-a4a0-4961-b283-a382559a00aa","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"6ced099f-3291-4c49-bc19-d1910f1accde","related_relationship":"","name_translated":{"fr":"Sommaire global de la qualité - Entités chimiques Demande d'essai clinique - Phase II (SGQ-EC (DEC - Phase II)","en":"Quality Overall Summary - Chemical Entities Clinical Trial Application - Phase II (QOS-CE (CTA - Phase II)"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Quality Overall Summary - Chemical Entities Clinical Trial Application - Phase II (QOS-CE (CTA - Phase II)","language":["en"],"created":"2021-06-02T15:12:00.425064","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/templates/quality-overall-summary-chemical-entities-clinical-trial-application-phase-2.html","last_modified":null,"position":4,"revision_id":"563cbbbe-124f-44f6-9c1d-6182cd3807ad","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"ea7ff183-a4a0-4961-b283-a382559a00aa","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"0f5d6c26-6ec6-406f-bdc8-52b74d7b19d3","related_relationship":"","name_translated":{"fr":"Sommaire global de la qualité - Entités chimiques Demande d'essai clinique - Phase II (SGQ-EC (DEC - Phase II)","en":"Quality Overall Summary - Chemical Entities Clinical Trial Application - Phase II (QOS-CE (CTA - Phase II)"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Quality Overall Summary - Chemical Entities Clinical Trial Application - Phase II (QOS-CE (CTA - Phase II)","language":["fr"],"created":"2021-06-02T15:12:00.425066","url":"https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/demandes-presentations/modeles/sommaire-global-qualite-entites-chimiques-demande-essai-clinique-phase-2.html","last_modified":null,"position":5,"revision_id":"563cbbbe-124f-44f6-9c1d-6182cd3807ad","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"ea7ff183-a4a0-4961-b283-a382559a00aa","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"eca484a6-fde0-456e-9f87-bf1a3ab10a16","related_relationship":"","name_translated":{"fr":"Sommaire global de la qualité - Entités chimiques Demandes d'essai clinique - Phase III (SGQ-EC (DEC - Phase III)","en":"Quality Overall Summary - Chemical Entities Clinical Trial Applications Phase III (QOS-CE (CTA - Phase III)"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Quality Overall Summary - Chemical Entities Clinical Trial Applications Phase III (QOS-CE (CTA - Phase III)","language":["en"],"created":"2021-06-02T15:12:00.425067","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/templates/quality-overall-summary-chemical-entities-clinical-trial-applications-phase-3.html","last_modified":null,"position":6,"revision_id":"563cbbbe-124f-44f6-9c1d-6182cd3807ad","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"ea7ff183-a4a0-4961-b283-a382559a00aa","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"a4c0d472-000e-41de-b760-17315ba9ac72","related_relationship":"","name_translated":{"fr":"Sommaire global de la qualité - Entités chimiques Demandes d'essai clinique - Phase III (SGQ-EC (DEC - Phase III)","en":"Quality Overall Summary - Chemical Entities Clinical Trial Applications Phase III (QOS-CE (CTA - Phase III)"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Quality Overall Summary - Chemical Entities Clinical Trial Applications Phase III (QOS-CE (CTA - Phase III)","language":["fr"],"created":"2021-06-02T15:12:00.425069","url":"https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/demandes-presentations/modeles/sommaire-global-qualite-entites-chimiques-demandes-essai-clinique-phase-3.html","last_modified":null,"position":7,"revision_id":"563cbbbe-124f-44f6-9c1d-6182cd3807ad","resource_type":"publication"}],"place_of_publication":[],"num_resources":8,"tags":[],"spatial":"","collection":"publication","org_title_at_publication":{"fr":"Santé Canada","en":"Health Canada"},"date_published":"2009-03-12 00:00:00","issuance":"","groups":[],"license_id":"ca-ogl-lgo","data_series_name":{"fr":"","en":""},"relationships_as_subject":[],"license_title":"Open Government Licence - Canada","restrictions":"unrestricted","organization":{"description":"","created":"2016-09-23T17:25:33.001625","title":"Health Canada | Santé Canada","name":"hc-sc","is_organization":true,"state":"active","image_url":"","revision_id":"6a0471e8-36e5-4217-8f72-563c83e6465a","type":"organization","id":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","approval_status":"approved"},"name":"ea7ff183-a4a0-4961-b283-a382559a00aa","isopen":false,"additional_notes":{"fr":"","en":""},"departmental_identification_number":"","notes":"To assist submission sponsors in preparing Clinical Trial Applications (CTAs) filed with Health Canada by outlining the Quality (chemistry and manufacturing) technical requirements for CTAs pursuant to Division C.05 of the Food and Drug Regulations.","owner_org":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","program_page_url":{"fr":"","en":""},"url":null,"audience":[],"gc_catalogue_number":"","license_url":"http://open.canada.ca/en/open-government-licence-canada","series_publication_dates":{"fr":"","en":""},"title":"Guidance Document - Quality (Chemistry and Manufacturing) Guidance: Clinical Trial Applications (CTAs) for Pharmaceuticals","revision_id":"563cbbbe-124f-44f6-9c1d-6182cd3807ad"}